Cargando…

GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients

Background: Control of ER-mitochondrial Ca(2+) fluxes is a critical checkpoint to determine cell fate under stress. The 75-kDa glucose-regulated protein (GRP75) is a key tether protein facilitating mitochondria-associated ER membrane (MAM) formation through the IP3R-GRP75-VDAC1 complex. Although GRP...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Qi, Fangzheng, Su, Huishan, Zhang, Chuanshan, Zhang, Qing, Chen, Ying, Chen, Ping, Su, Linjia, Chen, Yanan, Yang, Yuqi, Chen, Zhesheng, Zhang, Sihe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066115/
https://www.ncbi.nlm.nih.gov/pubmed/35541901
http://dx.doi.org/10.7150/ijbs.71571
_version_ 1784699736273453056
author Li, Jing
Qi, Fangzheng
Su, Huishan
Zhang, Chuanshan
Zhang, Qing
Chen, Ying
Chen, Ping
Su, Linjia
Chen, Yanan
Yang, Yuqi
Chen, Zhesheng
Zhang, Sihe
author_facet Li, Jing
Qi, Fangzheng
Su, Huishan
Zhang, Chuanshan
Zhang, Qing
Chen, Ying
Chen, Ping
Su, Linjia
Chen, Yanan
Yang, Yuqi
Chen, Zhesheng
Zhang, Sihe
author_sort Li, Jing
collection PubMed
description Background: Control of ER-mitochondrial Ca(2+) fluxes is a critical checkpoint to determine cell fate under stress. The 75-kDa glucose-regulated protein (GRP75) is a key tether protein facilitating mitochondria-associated ER membrane (MAM) formation through the IP3R-GRP75-VDAC1 complex. Although GRP75 contributes to cisplatin (CP)-resistance of ovarian cancer (OC), the underlying mechanisms are not clear. Methods: CP-resistant and -sensitive OC cell lines with GRP75 stable modulation were established. Confocal, PLA, co-IP, and TEM analysis were utilized to detect MAM integrity. Live cell Ca(2+) imaging, intracellular ATP, ROS, and NAD(+) assays were utilized to investigate ER-to-mitochondrial Ca(2+) transfer and mitochondrial bioenergetics. Western blot, flow cytometry, CCK-8, Δψm, and mPTP assays were utilized to examine apoptotic cell death. Bioinformatics, patient's specimens, and immunohistochemistry were conducted to obtain the clinical relevance for GRP75-facilitated MAM formation. Results: GRP75-faciliated MAM formation was enriched in CP-resistant OC cells. CP-exposure only increased MAM formation in CP-sensitive OC cells, and enrichment of GRP75 and VDAC1 at MAMs is indispensable to CP-resistance. Diminishing MAM integrity by GRP75-deficiency reduced ER-to-mitochondria Ca(2+) transfer, accelerated CP-induced mitochondrial dysfunction, provoked catastrophic ROS, and enhanced CP-triggered apoptotic cell death in OC cells. Clinical investigations confirmed the enrichment of GRP75-faciliated MAM formation in relapsed OC patients, and such enrichment was associated with the CP-resistance phenotype. Conclusion: GRP75-overexpression confers CP-resistance by distinctively managing MAM-facilitated Ca(2+) fluxes and the pro-survival ROS signal, whereas GRP75-deficiency induces cell death via bioenergetic crisis and apoptotic ROS accumulation in OC cells. Our results show that GRP75-faciliated MAM formation is a potential target to overcome CP-resistance of OC.
format Online
Article
Text
id pubmed-9066115
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-90661152022-05-09 GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients Li, Jing Qi, Fangzheng Su, Huishan Zhang, Chuanshan Zhang, Qing Chen, Ying Chen, Ping Su, Linjia Chen, Yanan Yang, Yuqi Chen, Zhesheng Zhang, Sihe Int J Biol Sci Research Paper Background: Control of ER-mitochondrial Ca(2+) fluxes is a critical checkpoint to determine cell fate under stress. The 75-kDa glucose-regulated protein (GRP75) is a key tether protein facilitating mitochondria-associated ER membrane (MAM) formation through the IP3R-GRP75-VDAC1 complex. Although GRP75 contributes to cisplatin (CP)-resistance of ovarian cancer (OC), the underlying mechanisms are not clear. Methods: CP-resistant and -sensitive OC cell lines with GRP75 stable modulation were established. Confocal, PLA, co-IP, and TEM analysis were utilized to detect MAM integrity. Live cell Ca(2+) imaging, intracellular ATP, ROS, and NAD(+) assays were utilized to investigate ER-to-mitochondrial Ca(2+) transfer and mitochondrial bioenergetics. Western blot, flow cytometry, CCK-8, Δψm, and mPTP assays were utilized to examine apoptotic cell death. Bioinformatics, patient's specimens, and immunohistochemistry were conducted to obtain the clinical relevance for GRP75-facilitated MAM formation. Results: GRP75-faciliated MAM formation was enriched in CP-resistant OC cells. CP-exposure only increased MAM formation in CP-sensitive OC cells, and enrichment of GRP75 and VDAC1 at MAMs is indispensable to CP-resistance. Diminishing MAM integrity by GRP75-deficiency reduced ER-to-mitochondria Ca(2+) transfer, accelerated CP-induced mitochondrial dysfunction, provoked catastrophic ROS, and enhanced CP-triggered apoptotic cell death in OC cells. Clinical investigations confirmed the enrichment of GRP75-faciliated MAM formation in relapsed OC patients, and such enrichment was associated with the CP-resistance phenotype. Conclusion: GRP75-overexpression confers CP-resistance by distinctively managing MAM-facilitated Ca(2+) fluxes and the pro-survival ROS signal, whereas GRP75-deficiency induces cell death via bioenergetic crisis and apoptotic ROS accumulation in OC cells. Our results show that GRP75-faciliated MAM formation is a potential target to overcome CP-resistance of OC. Ivyspring International Publisher 2022-04-11 /pmc/articles/PMC9066115/ /pubmed/35541901 http://dx.doi.org/10.7150/ijbs.71571 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Li, Jing
Qi, Fangzheng
Su, Huishan
Zhang, Chuanshan
Zhang, Qing
Chen, Ying
Chen, Ping
Su, Linjia
Chen, Yanan
Yang, Yuqi
Chen, Zhesheng
Zhang, Sihe
GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients
title GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients
title_full GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients
title_fullStr GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients
title_full_unstemmed GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients
title_short GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients
title_sort grp75-faciliated mitochondria-associated er membrane (mam) integrity controls cisplatin-resistance in ovarian cancer patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066115/
https://www.ncbi.nlm.nih.gov/pubmed/35541901
http://dx.doi.org/10.7150/ijbs.71571
work_keys_str_mv AT lijing grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT qifangzheng grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT suhuishan grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT zhangchuanshan grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT zhangqing grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT chenying grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT chenping grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT sulinjia grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT chenyanan grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT yangyuqi grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT chenzhesheng grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients
AT zhangsihe grp75faciliatedmitochondriaassociatedermembranemamintegritycontrolscisplatinresistanceinovariancancerpatients